MicroRNA markers in first episode schizophrenia
Part of Mental health clinical trials.
This study looks at tiny molecules called microRNAs in the blood of people having their first episode of schizophrenia. It aims to find markers that could help guide treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are having your first episode of psychosis and have been diagnosed with schizophrenia or a related condition.
- You currently have moderate or more severe symptoms like hallucinations or disorganized thinking.
- You have taken antipsychotic medication for a total of 2 weeks or less in your lifetime.
- You are between 15 and 40 years old.
- You are about to start treatment with either aripiprazole or risperidone, or are already taking one of these.
- You are able to give your own consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who have had psychosis for less than 4 years to understand how their symptoms change over time and how they respond to treatment. By using brain scans and other tests, researchers hope to find better ways to personalize care for early psychosis.
This study builds a database of brain-signal measurements to help find “biomarkers” that may point to schizophrenia or related mental illnesses. Depending on whether you have a mental health diagnosis or you’re healthy, the study will collect information and brain data to compare groups.
This study uses brain scans to find markers that can predict how well antipsychotic medications work in people having their first episode of psychosis. It aims to help doctors choose the right treatment earlier.
This study looks at tiny particles called exosomes in your blood and how small molecules inside them called microRNAs may affect thinking and memory in people with a first episode of schizophrenia. If you join, your blood will be used to help find new ways to understand and treat cognitive symptoms.
This study looks at whether special body and brain markers can predict how a person’s symptoms change over two years after a first psychotic episode. It may also help doctors understand who responds better to treatment, so future care can be more personalized.
This study looks for a biological signature in the brain and blood to help doctors tell apart different types of psychosis early on. It may help people with schizophrenia, bipolar disorder, or major depression understand their condition better.
Hear when a new Schizoaffective Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.